Scitbio Pharmaceuticals focuses on the research and development, commercialization and operation of innovative drugs, and creates new biological drugs with significant clinical value in the field of oncology.
We use our core technologies to develop innovative and differentiated drug pipelines to achieve anti-tumor effects that cannot be achieved with traditional drug combination therapies.
We carry out innovative cooperation with the world's top academic institutions and biomedical companies, and comprehensively promote the research and development of the next generation of innovative therapies through independent innovation and diversified cooperation.
Anti-tumor combination drugs
auranofin and celecoxib
An anti-tumor combination drug. Research results show that celecoxib can significantly improve the anti-tumor effect of auranofin. We have conducted multi-angle and multi-level verification studies on this, clarified the synergistic mechanism of auranofin and celecoxib, and established a solid foundation for application theory. Based on this, we proposed for the first time a new drug strategy for tumor treatment based on the combination of auranofin and celecoxib, which will promote the application of auranofin and celecoxib in the clinical treatment of tumors and greatly shorten the time of drug treatment. Time from discovery to clinical translation.
More details
Careers
Join our team of outstanding experts in business, science and technology and become part of our innovative research team.
Find a position that interests you, submit an application and become a member of our team!
Current job opportunities